Splinter T A, Carney D N, Teeling M, Oosterom R
Univ. Hospital Dijkzigt, Dept. of Oncology, Rotterdam.
J Cancer Res Clin Oncol. 1988;114(6):641-3. doi: 10.1007/BF00398191.
Neuron-specific enolase (NSE) was measured in serum samples of 35 patients with small cell lung cancer and 10 control patients. The samples were collected during 10 days after the first course of chemotherapy, in order to investigate whether changes of NSE had a predictive value of tumour response. Three patterns of change of NSE were observed. Pattern 1 showed an increase of serum NSE with a maximum value more than 1.5 times the pretreatment level (n = 17); pattern 2 involved no increase at all or less than 1.5 times the pretreatment level (n = 14); pattern 3 showed a continuous decrease (n = 5). No relationship between the three patterns of change and the tumour response was observed. Only an NSE level less than 10 ng/ml at the time of start of the second course predicted a major response.
在35例小细胞肺癌患者和10例对照患者的血清样本中检测了神经元特异性烯醇化酶（NSE）。样本在首个化疗疗程后的10天内采集，以研究NSE的变化是否对肿瘤反应具有预测价值。观察到NSE的三种变化模式。模式1表现为血清NSE升高，最大值超过预处理水平的1.5倍（n = 17）；模式2为根本没有升高或低于预处理水平的1.5倍（n = 14）；模式3表现为持续下降（n = 5）。未观察到三种变化模式与肿瘤反应之间的关系。仅第二个疗程开始时NSE水平低于10 ng/ml可预测主要反应。
